LY2784544 is identified as being highly selective for JAK2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.
温馨提示:LY2784544 (Gandotinib),品质稳定,纯度>98+%,仅供实验使用.产品质量严格控制,保证品质。
南京百鑫德诺生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!